Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-EARLY: Acoramidis for Prevention of Transthyretin Amyloidosis in Young At-Risk Adults
jRCT2071250116Phase 3Recruiting
- Sponsor
- Eidos Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing Acoramidis with Placebo (2 arms). Primary endpoint: Time to development of ATTR (ATTR-CM or ATTR-PN). Started Dec 2025; status: recruiting.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on jRCT2071250116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250116.